Charles River Laboratories Intl. Inc vs SoFi Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.01 (market cap $14.23B), while SoFi Technologies Inc trades at $15.77 (market cap $20.16B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and SoFi Technologies Inc for 60 Days on average.
| CRL | SOFI | |
|---|---|---|
Market Cap | $14.23B | $20.16B |
Volume | 1,176,885 | 49,646,331 |
Sector | Health | Financials |
52-Week High | $310.77 | $32.21 |
52-Week Low | $149.93 | $15.15 |
Typical Hold Time | 33 Days | 60 Days |
Enterprise Value | $17.06B | $20.30B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
SoFi Technologies (SOFI) trades at $15.66, down 0.64% on the day and near its 52-week low, reflecting bearish technical signals. The company reported strong revenue growth to $3.61 billion in 2025 with a net income of $481.32 million, but negative operating cash flow and high leverage remain concerns. Analyst sentiment is mixed with a consensus price target of $21.58, implying significant upside, while recent news highlights growth in loan originations and stablecoin initiatives.
The outlook for SOFI hinges on sustaining profitability amid competitive pressures and interest rate sensitivity. Upside potential exists from execution on guidance and market share gains, but risks include persistent cash burn and macroeconomic headwinds. Investors should weigh the growth trajectory against valuation premiums and operational challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →